574 related articles for article (PubMed ID: 19397277)
1. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
2. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2010 Jan; 23(1):6-10. PubMed ID: 19954191
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
J Pharmacol Exp Ther; 2007 Jul; 322(1):408-19. PubMed ID: 17468298
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
[TBL] [Abstract][Full Text] [Related]
5. Cytoprotective effect of anthocyanins against doxorubicin-induced toxicity in H9c2 cardiomyocytes in relation to their antioxidant activities.
Choi EH; Chang HJ; Cho JY; Chun HS
Food Chem Toxicol; 2007 Oct; 45(10):1873-81. PubMed ID: 17524543
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.
Salvatorelli E; Menna P; Gonzalez Paz O; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
J Pharmacol Exp Ther; 2012 May; 341(2):474-83. PubMed ID: 22338034
[TBL] [Abstract][Full Text] [Related]
7. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.
Menna P; Minotti G; Salvatorelli E
Cell Biol Toxicol; 2007 Jan; 23(1):49-62. PubMed ID: 17031515
[TBL] [Abstract][Full Text] [Related]
8. Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.
Salvatorelli E; Guarnieri S; Menna P; Liberi G; Calafiore AM; Mariggiò MA; Mordente A; Gianni L; Minotti G
J Biol Chem; 2006 Apr; 281(16):10990-1001. PubMed ID: 16423826
[TBL] [Abstract][Full Text] [Related]
9. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
10. The role of biotransformation in anthracycline-induced cardiotoxicity in mice.
de Jong J; Schoofs PR; Snabilié AM; Bast A; van der Vijgh WJ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139
[TBL] [Abstract][Full Text] [Related]
11. The influence of doxorubicin and 4'-epi-doxorubicin on lipid peroxidation in mouse heart, lungs and liver. Part II.
Pierściński G; Drzewoski J; Nowak D
Pol J Pharmacol; 1994; 46(1-2):55-9. PubMed ID: 7981772
[TBL] [Abstract][Full Text] [Related]
12. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
Menna P; Recalcati S; Cairo G; Minotti G
Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
[TBL] [Abstract][Full Text] [Related]
13. Human heart cytosolic reductases and anthracycline cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity.
Swift L; McHowat J; Sarvazyan N
Cancer Res; 2003 Sep; 63(18):5992-8. PubMed ID: 14522926
[TBL] [Abstract][Full Text] [Related]
15. Enhanced toxicity and ROS generation by doxorubicin in primary cultures of cardiomyocytes from neonatal metallothionein-I/II null mice.
Fu Z; Guo J; Jing L; Li R; Zhang T; Peng S
Toxicol In Vitro; 2010 Sep; 24(6):1584-91. PubMed ID: 20600803
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of naringenin-7-O-glucoside against oxidative stress induced by doxorubicin in H9c2 cardiomyocytes.
Han XZ; Gao S; Cheng YN; Sun YZ; Liu W; Tang LL; Ren DM
Biosci Trends; 2012 Feb; 6(1):19-25. PubMed ID: 22426099
[TBL] [Abstract][Full Text] [Related]
17. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines.
Menna P; Salvatorelli E; Giampietro R; Liberi G; Teodori G; Calafiore AM; Minotti G
Chem Res Toxicol; 2002 Sep; 15(9):1179-89. PubMed ID: 12230412
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.
Minotti G; Licata S; Saponiero A; Menna P; Calafiore AM; Di Giammarco G; Liberi G; Animati F; Cipollone A; Manzini S; Maggi CA
Chem Res Toxicol; 2000 Dec; 13(12):1336-41. PubMed ID: 11123976
[TBL] [Abstract][Full Text] [Related]
20. Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.
Minotti G; Parlani M; Salvatorelli E; Menna P; Cipollone A; Animati F; Maggi CA; Manzini S
Br J Pharmacol; 2001 Nov; 134(6):1271-8. PubMed ID: 11704647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
